Search
for

    Sort by

    Research 31–60 of 1000+

    1. Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches Scientific Reports · 2025
    2. 484 FDA cleared devices produce inconsistent platelet-rich plasma product Journal of Investigative Dermatology · 2020
    3. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods Pharmaceuticals · 2021 · 42 citations
    4. Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors PLOS ONE · 2015 · 17 citations
    5. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) Figshare · 2026
    6. Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions Journal of Cosmetic Dermatology · 2024
    7. The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database Brain Sciences · 2023
    8. Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents Letters in Applied NanoBioScience · 2021
    9. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical <i>in silico/in vitro</i> screening methods bioRxiv (Cold Spring Harbor Laboratory) · 2020
    10. The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis. Inpharma Weekly · 2007
    11. Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System Scientific Reports · 2020 · 11 citations
    12. Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs Scholar Commons (University of South Carolina) · 2013 · 1 citations
    13. Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program Annals of Medicine and Surgery · 2026
    14. Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system Frontiers in Medicine · 2026
    15. Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system Andrology · 2024
    16. Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss Digital Access to Scholarship at Harvard (DASH) (Harvard University) · 2005
    17. 112 Post-Finasteride Syndrome – Outcomes of FDA Database The Journal of Sexual Medicine · 2016
    18. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System Scientific Reports · 2020 · 58 citations
    19. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system Frontiers in Pharmacology · 2024 · 30 citations
    20. Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024 Pharmaceuticals · 2025 · 8 citations
    21. Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data Journal of the American Academy of Dermatology · 2021 · 6 citations
    22. Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules BMC chemistry · 2022 · 3 citations
    23. A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system Scientific Reports · 2025 · 2 citations
    24. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) The Aging Male · 2026
    25. Innovations in skin microphysiological systems for nonclinical testing and FDA modernization Microsystems & Nanoengineering · 2026
    26. PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE 2021
    27. 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) Sleep · 2020
    28. 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database The Journal of Sexual Medicine · 2016
    29. A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir Molecular Brain · 2020 · 3 citations
    30. A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System Pharmacology Research & Perspectives · 2025 · 2 citations